Rekvina Labs Ltd.
| BSE: 526075 | Sector: Health care |
| NSE: N.A. | ISIN Code: INE092O01028 |
| BSE 00:00 | 11 Mar | Rekvina Labs Ltd |
| NSE 05:30 | 01 Jan | Rekvina Labs Ltd |
| OPEN | 4.17 |
| PREVIOUS CLOSE | 4.17 |
| VOLUME | 1 |
| 52-Week high | 5.05 |
| 52-Week low | 3.95 |
| P/E | |
| Mkt Cap.(Rs cr) | 3 |
| Buy Price | 4.15 |
| Buy Qty | 1000.00 |
| Sell Price | 4.20 |
| Sell Qty | 8.00 |
Rekvina Labs Ltd. (REKVINALABS) - Net Profit
Net Profit
| COMPANY | LATEST(Rs) | CHG | CHG(%) | Net Profit (Rs crore) |
| Sun Pharma.Inds. | 485.40 | -17.35 | -3.45 | 3211.14 |
| Dr Reddy's Labs | 5024.45 | -75.95 | -1.49 | 2937.70 |
| Cipla | 732.80 | -34.10 | -4.45 | 2318.17 |
| Aurobindo Pharma | 743.35 | -37.55 | -4.81 | 1872.74 |
| Cadila Health. | 376.05 | -7.85 | -2.04 | 1412.90 |
| Divi's Lab. | 3021.25 | -117.80 | -3.75 | 1372.71 |
| Glenmark Pharma. | 454.10 | -16.60 | -3.53 | 1354.55 |
| Alkem Lab | 2831.10 | 88.40 | 3.22 | 1264.42 |
| Alembic Pharma | 934.35 | 18.70 | 2.04 | 969.40 |
| Torrent Pharma. | 2649.00 | -10.70 | -0.40 | 938.51 |
| P & G Health Ltd | 4833.25 | -126.80 | -2.56 | 838.72 |
| Lupin | 979.55 | -36.45 | -3.59 | 727.55 |
| Ipca Labs. | 2065.90 | -69.85 | -3.27 | 652.46 |
| Abbott India | 15968.05 | -25.00 | -0.16 | 592.93 |
| Fortis Health. | 136.15 | 1.25 | 0.93 | 513.33 |
| Pfizer | 4873.90 | -39.35 | -0.80 | 509.13 |
| Natco Pharma | 852.20 | 1.40 | 0.16 | 474.50 |
| Apollo Hospitals | 1948.65 | 129.70 | 7.13 | 470.30 |
| Granules India | 360.60 | -2.85 | -0.78 | 444.07 |
| Ajanta Pharma | 1562.35 | -1.75 | -0.11 | 441.13 |
Quick Links for Rekvina Labs:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
